En undersøgelse, der sammenligner kombinationen af Pembrolizumab og Sacituzumab Govitecan versus Sacituzumab Govitecan alene i behandlingen af avanceret urothelial cancer
Et fase III randomiseret forsøg med Pembrolizumab i kombination med Sacituzumab Govitecan vs Sacituzumab Govitecan alene i anti-PD(L)1-resistent avanceret urothelial cancer
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan-hziy to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan-hziy may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To compare overall survival (OS) between the therapy of physician choice (TPC) arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
SECONDARY OBJECTIVES:
I. To compare the progression free survival (PFS) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
II. To evaluate overall response rate (ORR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
III. To evaluate clinical benefit rate (complete response [CR]/partial response [PR] /stable disease [SD]) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To evaluate duration of response (DoR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To evaluate toxicity of the Sacituzumab govitecan-hziy + pembrolizumab arm using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
EXPLORATORY HEALTH RELATED QUALITY OF LIFE (HRQOL) OBJECTIVES:
I. To compare HRQOL, as assessed by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at 6 months.
II. To compare HRQOL change from baseline, as assessed by the FBISI-18 summary score, for patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at baseline, 3, 6, and 12 months.
III. To compare the change in patient-reported fatigue from baseline and across 3, 6, and 12 months as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) summary score; change from baseline will be compared between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To compare quality-adjusted survival (overall survival x health utility score assessed by the European Quality of Life Five Dimension Five Level [EQ-5D-5L]) between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To compare time to HRQOL deterioration in global HRQOL, as measured by the FBISI-18 disease-related physical symptom subscale (FBISI-18 disease-related symptoms (DRS) in the physical emotional domains [DRS-P]), between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive TPC with carboplatin or cisplatin intravenously (IV) on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.
ARM B: Patients receive sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 35 cycles or for 2 years of pembrolizumab in the absence of disease progression or unacceptable toxicity. Cycles of sacituzumab govitecan-hziy repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study.
After completion of study treatment, patients are followed up at 30 days then once a year for 5 years from the date of randomization.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85004
- Rekruttering
- Cancer Center at Saint Joseph's
-
Ledende efterforsker:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
-
California
-
Irvine, California, Forenede Stater, 92612
- Rekruttering
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Ledende efterforsker:
- Nataliya Mar
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Ledende efterforsker:
- Nataliya Mar
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
- Rekruttering
- UF Health Cancer Institute - Gainesville
-
Ledende efterforsker:
- Daniel V. Araujo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Hospital/Winship Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Ledende efterforsker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Forenede Stater, 30308
- Rekruttering
- Emory University Hospital Midtown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-946-7447
-
Ledende efterforsker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Forenede Stater, 30342
- Rekruttering
- Emory Saint Joseph's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-851-7115
-
Ledende efterforsker:
- Jacqueline T. Brown
-
-
Idaho
-
Coeur d'Alene, Idaho, Forenede Stater, 83814
- Rekruttering
- Kootenai Health - Coeur d'Alene
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Post Falls, Idaho, Forenede Stater, 83854
- Rekruttering
- Kootenai Clinic Cancer Services - Post Falls
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Forenede Stater, 83864
- Rekruttering
- Kootenai Clinic Cancer Services - Sandpoint
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rekruttering
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Ledende efterforsker:
- Karine Tawagi
-
Danville, Illinois, Forenede Stater, 61832
- Rekruttering
- Carle at The Riverfront
-
Ledende efterforsker:
- Priyank P. Patel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
Decatur, Illinois, Forenede Stater, 62526
- Rekruttering
- Cancer Care Specialists of Illinois - Decatur
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Forenede Stater, 62526
- Rekruttering
- Decatur Memorial Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, Forenede Stater, 62401
- Rekruttering
- Carle Physician Group-Effingham
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Ledende efterforsker:
- Priyank P. Patel
-
Effingham, Illinois, Forenede Stater, 62401
- Rekruttering
- Crossroads Cancer Center
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Mattoon, Illinois, Forenede Stater, 61938
- Rekruttering
- Carle Physician Group-Mattoon/Charleston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Ledende efterforsker:
- Priyank P. Patel
-
Normal, Illinois, Forenede Stater, 61761
- Rekruttering
- Carle BroMenn Medical Center
-
Ledende efterforsker:
- Priyank P. Patel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
Normal, Illinois, Forenede Stater, 61761
- Rekruttering
- Carle Cancer Institute Normal
-
Ledende efterforsker:
- Priyank P. Patel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
O'Fallon, Illinois, Forenede Stater, 62269
- Rekruttering
- Cancer Care Center of O'Fallon
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
O'Fallon, Illinois, Forenede Stater, 62269
- Rekruttering
- HSHS Saint Elizabeth's Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Shiloh, Illinois, Forenede Stater, 62269
- Rekruttering
- Memorial Hospital East
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-747-9912
- E-mail: dschwab@wustl.edu
-
Ledende efterforsker:
- Melissa A. Reimers
-
Springfield, Illinois, Forenede Stater, 62702
- Rekruttering
- Southern Illinois University School of Medicine
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Springfield, Illinois, Forenede Stater, 62702
- Rekruttering
- Springfield Clinic
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-444-7541
-
Springfield, Illinois, Forenede Stater, 62781
- Rekruttering
- Springfield Memorial Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-528-7541
- E-mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Forenede Stater, 61801
- Rekruttering
- Carle Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Ledende efterforsker:
- Priyank P. Patel
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- Rekruttering
- Mary Greeley Medical Center
-
Ledende efterforsker:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Ames, Iowa, Forenede Stater, 50010
- Rekruttering
- McFarland Clinic - Ames
-
Ledende efterforsker:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-239-4734
- E-mail: ksoder@mcfarlandclinic.com
-
Boone, Iowa, Forenede Stater, 50036
- Suspenderet
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Forenede Stater, 52403
- Rekruttering
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 319-365-4673
-
Ledende efterforsker:
- Deborah W. Wilbur
-
Cedar Rapids, Iowa, Forenede Stater, 52403
- Rekruttering
- Oncology Associates at Mercy Medical Center
-
Ledende efterforsker:
- Deborah W. Wilbur
-
Kontakt:
- Site Public Contact
- Telefonnummer: 319-363-2690
-
Fort Dodge, Iowa, Forenede Stater, 50501
- Rekruttering
- McFarland Clinic - Trinity Cancer Center
-
Ledende efterforsker:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Jefferson, Iowa, Forenede Stater, 50129
- Suspenderet
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Forenede Stater, 50158
- Rekruttering
- McFarland Clinic - Marshalltown
-
Ledende efterforsker:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
-
Kansas
-
Hays, Kansas, Forenede Stater, 67601
- Rekruttering
- HaysMed
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-623-5774
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- University of Kansas Cancer Center
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Lawrence, Kansas, Forenede Stater, 66044
- Rekruttering
- Lawrence Memorial Hospital
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-505-2800
- E-mail: Stephanie.Norris@LMH.ORG
-
Olathe, Kansas, Forenede Stater, 66061
- Rekruttering
- The University of Kansas Cancer Center - Olathe
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-1569
- E-mail: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Forenede Stater, 66210
- Rekruttering
- University of Kansas Cancer Center-Overland Park
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Salina, Kansas, Forenede Stater, 67401
- Rekruttering
- Salina Regional Health Center
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-452-7038
- E-mail: mleepers@srhc.com
-
Topeka, Kansas, Forenede Stater, 66606
- Rekruttering
- University of Kansas Health System Saint Francis Campus
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-295-8000
-
Westwood, Kansas, Forenede Stater, 66205
- Rekruttering
- University of Kansas Hospital-Westwood Cancer Center
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40202
- Rekruttering
- The James Graham Brown Cancer Center at University of Louisville
-
Ledende efterforsker:
- Rohit Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-562-3429
-
Louisville, Kentucky, Forenede Stater, 40245
- Rekruttering
- UofL Health Medical Center Northeast
-
Ledende efterforsker:
- Rohit Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-852-2755
- E-mail: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Rekruttering
- Louisiana Hematology Oncology Associates LLC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 225-215-1353
- E-mail: clinicalresearch@marybird.com
-
Ledende efterforsker:
- Scott E. Delacroix
-
Metairie, Louisiana, Forenede Stater, 70002
- Rekruttering
- Mary Bird Perkins Cancer Center - Metairie
-
Ledende efterforsker:
- Scott E. Delacroix
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-584-6990
-
-
Massachusetts
-
Worcester, Massachusetts, Forenede Stater, 01655
- Rekruttering
- UMass Memorial Medical Center - University Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 508-856-3216
- E-mail: cancer.research@umassmed.edu
-
Ledende efterforsker:
- Kriti Mittal
-
-
Michigan
-
Brighton, Michigan, Forenede Stater, 48114
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Houssam Y. Hariri
-
Canton, Michigan, Forenede Stater, 48188
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Houssam Y. Hariri
-
Chelsea, Michigan, Forenede Stater, 48118
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Houssam Y. Hariri
-
Lansing, Michigan, Forenede Stater, 48912
- Rekruttering
- University of Michigan Health - Sparrow Lansing
-
Kontakt:
- Site Public Contact
- Telefonnummer: 517-364-3712
- E-mail: harsha.trivedi@umhsparrow.org
-
Ledende efterforsker:
- Houssam Y. Hariri
-
Livonia, Michigan, Forenede Stater, 48154
- Rekruttering
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Houssam Y. Hariri
-
Pontiac, Michigan, Forenede Stater, 48341
- Rekruttering
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Houssam Y. Hariri
-
Ypsilanti, Michigan, Forenede Stater, 48197
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Ledende efterforsker:
- Houssam Y. Hariri
-
-
Minnesota
-
Brainerd, Minnesota, Forenede Stater, 56401
- Rekruttering
- Essentia Health Saint Joseph's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Ledende efterforsker:
- Bret E. Friday
-
Coon Rapids, Minnesota, Forenede Stater, 55433
- Rekruttering
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Deer River, Minnesota, Forenede Stater, 56636
- Rekruttering
- Essentia Health - Deer River Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Ledende efterforsker:
- Bret E. Friday
-
Duluth, Minnesota, Forenede Stater, 55805
- Rekruttering
- Essentia Health Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Ledende efterforsker:
- Bret E. Friday
-
Edina, Minnesota, Forenede Stater, 55435
- Rekruttering
- Fairview Southdale Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Edina, Minnesota, Forenede Stater, 55435
- Rekruttering
- Minnesota Oncology - Edina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Hibbing, Minnesota, Forenede Stater, 55746
- Rekruttering
- Essentia Health Hibbing Clinic
-
Ledende efterforsker:
- Bret E. Friday
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
-
Marshall, Minnesota, Forenede Stater, 56258
- Rekruttering
- Avera Cancer Institute at Marshall
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-mail: OncRegulatory@avera.org
-
Ledende efterforsker:
- Ryan A. Vaca
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Rekruttering
- Abbott-Northwestern Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Saint Louis Park, Minnesota, Forenede Stater, 55416
- Rekruttering
- Park Nicollet Clinic - Saint Louis Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Saint Paul, Minnesota, Forenede Stater, 55101
- Rekruttering
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Saint Paul, Minnesota, Forenede Stater, 55102
- Rekruttering
- United Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
Sandstone, Minnesota, Forenede Stater, 55072
- Rekruttering
- Essentia Health Sandstone
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Ledende efterforsker:
- Bret E. Friday
-
Virginia, Minnesota, Forenede Stater, 55792
- Rekruttering
- Essentia Health Virginia Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Ledende efterforsker:
- Bret E. Friday
-
-
Missouri
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Rekruttering
- Saint Francis Medical Center
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-334-2230
- E-mail: sfmc@sfmc.net
-
City of Saint Peters, Missouri, Forenede Stater, 63376
- Rekruttering
- Siteman Cancer Center at Saint Peters Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Ledende efterforsker:
- Melissa A. Reimers
-
Creve Coeur, Missouri, Forenede Stater, 63141
- Rekruttering
- Siteman Cancer Center at West County Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Ledende efterforsker:
- Melissa A. Reimers
-
Farmington, Missouri, Forenede Stater, 63640
- Rekruttering
- Parkland Health Center - Farmington
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Kansas City, Missouri, Forenede Stater, 64154
- Rekruttering
- University of Kansas Cancer Center - North
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Kansas City, Missouri, Forenede Stater, 64108
- Rekruttering
- University Health Truman Medical Center
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-404-4375
-
Kansas City, Missouri, Forenede Stater, 64116
- Rekruttering
- University of Kansas Cancer Center - Briarcliff
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
-
Lee's Summit, Missouri, Forenede Stater, 64064
- Rekruttering
- University of Kansas Cancer Center - Lee's Summit
-
Ledende efterforsker:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Sainte Genevieve, Missouri, Forenede Stater, 63670
- Rekruttering
- Sainte Genevieve County Memorial Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Ledende efterforsker:
- Melissa A. Reimers
-
St Louis, Missouri, Forenede Stater, 63129
- Rekruttering
- Siteman Cancer Center-South County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Ledende efterforsker:
- Melissa A. Reimers
-
St Louis, Missouri, Forenede Stater, 63136
- Rekruttering
- Siteman Cancer Center at Christian Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-mail: info@siteman.wustl.edu
-
Ledende efterforsker:
- Melissa A. Reimers
-
St Louis, Missouri, Forenede Stater, 63131
- Rekruttering
- Missouri Baptist Medical Center
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sullivan, Missouri, Forenede Stater, 63080
- Rekruttering
- Missouri Baptist Sullivan Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Forenede Stater, 59711
- Rekruttering
- Community Hospital of Anaconda
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Billings, Montana, Forenede Stater, 59101
- Rekruttering
- Billings Clinic Cancer Center
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-996-2663
- E-mail: research@billingsclinic.org
-
Bozeman, Montana, Forenede Stater, 59715
- Rekruttering
- Bozeman Health Deaconess Hospital
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Forenede Stater, 59405
- Rekruttering
- Benefis Sletten Cancer Institute
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Forenede Stater, 59901
- Rekruttering
- Logan Health Medical Center
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Missoula, Montana, Forenede Stater, 59804
- Rekruttering
- Community Medical Center
-
Ledende efterforsker:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Rekruttering
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
Ledende efterforsker:
- Jacob B. Reibel
-
-
New Jersey
-
Livingston, New Jersey, Forenede Stater, 07039
- Rekruttering
- Cooperman Barnabas Medical Center
-
Ledende efterforsker:
- Biren Saraiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-322-5200
-
Long Branch, New Jersey, Forenede Stater, 07740
- Rekruttering
- Monmouth Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-923-6564
- E-mail: mary.danish@rwjbh.org
-
Ledende efterforsker:
- Biren Saraiya
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Rekruttering
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Ledende efterforsker:
- Biren Saraiya
-
Newark, New Jersey, Forenede Stater, 07101
- Rekruttering
- Rutgers New Jersey Medical School
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Ledende efterforsker:
- Biren Saraiya
-
Somerville, New Jersey, Forenede Stater, 08876
- Rekruttering
- Robert Wood Johnson University Hospital Somerset
-
Ledende efterforsker:
- Biren Saraiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 908-685-2481
- E-mail: Siby.Varughese@rwjbh.org
-
Toms River, New Jersey, Forenede Stater, 08755
- Rekruttering
- Community Medical Center
-
Ledende efterforsker:
- Biren Saraiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-557-8294
- E-mail: Lennette.Gonzales@rwjbh.org
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Rekruttering
- Roswell Park Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Ledende efterforsker:
- Ellis G. Levine
-
Stony Brook, New York, Forenede Stater, 11794
- Rekruttering
- Stony Brook University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-862-2215
-
Ledende efterforsker:
- Judy Huang
-
Williamsville, New York, Forenede Stater, 14221
- Rekruttering
- Roswell Park Amherst Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Ledende efterforsker:
- Ellis G. Levine
-
-
North Carolina
-
Hendersonville, North Carolina, Forenede Stater, 28791
- Rekruttering
- Margaret R Pardee Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 828-696-4716
- E-mail: pardeecancerresearch@unchealth.unc.edu
-
Ledende efterforsker:
- John K. Hill
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58103
- Rekruttering
- Essentia Health Cancer Center-South University Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Ledende efterforsker:
- Bret E. Friday
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- Ohio State University Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
Ledende efterforsker:
- Yuanquan Yang
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Rekruttering
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Ledende efterforsker:
- Adanma Anji Ayanambakkam Attanathi
-
-
Pennsylvania
-
Danville, Pennsylvania, Forenede Stater, 17822
- Rekruttering
- Geisinger Medical Center
-
Ledende efterforsker:
- Sorab Gupta
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Dickson City, Pennsylvania, Forenede Stater, 18519
- Rekruttering
- Geisinger Cancer Center Dickson City
-
Ledende efterforsker:
- Sorab Gupta
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-204-6081
- E-mail: cancerresearch@geisinger.edu
-
Erie, Pennsylvania, Forenede Stater, 16505
- Rekruttering
- UPMC Hillman Cancer Center Erie
-
Ledende efterforsker:
- Leonard J. Appleman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Erie, Pennsylvania, Forenede Stater, 16544
- Rekruttering
- Saint Vincent Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 814-452-5000
-
Ledende efterforsker:
- Alexander Helfand
-
Greensburg, Pennsylvania, Forenede Stater, 15601
- Rekruttering
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 724-838-1900
-
Ledende efterforsker:
- Leonard J. Appleman
-
Harrisburg, Pennsylvania, Forenede Stater, 17109
- Rekruttering
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-724-6765
- E-mail: klitchfield@PINNACLEHEALTH.org
-
Ledende efterforsker:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Forenede Stater, 17033-0850
- Rekruttering
- Penn State Milton S Hershey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-531-3779
- E-mail: CTO@hmc.psu.edu
-
Ledende efterforsker:
- Monika Joshi
-
Indiana, Pennsylvania, Forenede Stater, 15701
- Rekruttering
- IRMC Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-389-5208
- E-mail: haneydl@upmc.edu
-
Ledende efterforsker:
- Leonard J. Appleman
-
Jefferson Hills, Pennsylvania, Forenede Stater, 15025
- Rekruttering
- Jefferson Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-359-3043
- E-mail: ddefazio@wpahs.org
-
Ledende efterforsker:
- Alexander Helfand
-
Lewisburg, Pennsylvania, Forenede Stater, 17837
- Rekruttering
- Geisinger Medical Oncology-Lewisburg
-
Ledende efterforsker:
- Sorab Gupta
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-523-9200
- E-mail: cancerresearch@geisinger.edu
-
Mechanicsburg, Pennsylvania, Forenede Stater, 17050
- Rekruttering
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-389-5208
- E-mail: haneydl@upmc.edu
-
Ledende efterforsker:
- Leonard J. Appleman
-
Monroeville, Pennsylvania, Forenede Stater, 15146
- Rekruttering
- Forbes Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-858-7746
-
Ledende efterforsker:
- Alexander Helfand
-
Monroeville, Pennsylvania, Forenede Stater, 15146
- Rekruttering
- UPMC Hillman Cancer Center - Monroeville
-
Ledende efterforsker:
- Leonard J. Appleman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Natrona Heights, Pennsylvania, Forenede Stater, 15065
- Rekruttering
- Allegheny Valley Hospital
-
Kontakt:
- Site Public Contact
- E-mail: Dawnmarie.DeFazio@ahn.org
-
Ledende efterforsker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- West Penn Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-578-5000
-
Ledende efterforsker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Forenede Stater, 15215
- Rekruttering
- UPMC-Saint Margaret
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-784-4900
-
Ledende efterforsker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Forenede Stater, 15237
- Rekruttering
- UPMC-Passavant Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-367-6454
-
Ledende efterforsker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- Rekruttering
- Allegheny General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-284-2000
-
Ledende efterforsker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- UPMC Hillman Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-647-8073
-
Ledende efterforsker:
- Leonard J. Appleman
-
Seneca, Pennsylvania, Forenede Stater, 16346
- Rekruttering
- UPMC Cancer Center at UPMC Northwest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 814-676-7900
-
Ledende efterforsker:
- Leonard J. Appleman
-
Uniontown, Pennsylvania, Forenede Stater, 15401
- Rekruttering
- UPMC Cancer Center-Uniontown
-
Kontakt:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Ledende efterforsker:
- Leonard J. Appleman
-
Washington, Pennsylvania, Forenede Stater, 15301
- Rekruttering
- UPMC Cancer Center-Washington
-
Kontakt:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Ledende efterforsker:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Forenede Stater, 19611
- Rekruttering
- Reading Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-988-9323
-
Ledende efterforsker:
- Terrence P. Cescon
-
Wexford, Pennsylvania, Forenede Stater, 15090
- Rekruttering
- Wexford Health and Wellness Pavilion
-
Kontakt:
- Site Public Contact
- E-mail: Dawnmarie.DeFazio@ahn.org
-
Ledende efterforsker:
- Alexander Helfand
-
Wilkes-Barre, Pennsylvania, Forenede Stater, 18711
- Rekruttering
- Geisinger Wyoming Valley/Henry Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-mail: HemonCCTrials@geisinger.edu
-
Ledende efterforsker:
- Sorab Gupta
-
-
South Dakota
-
Aberdeen, South Dakota, Forenede Stater, 57401
- Rekruttering
- Avera Cancer Institute-Aberdeen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-622-8700
- E-mail: oncregulatory@avera.org
-
Ledende efterforsker:
- Ryan A. Vaca
-
Mitchell, South Dakota, Forenede Stater, 57301
- Rekruttering
- Avera Cancer Institute - Mitchell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-322-3096
- E-mail: OncRegulatory@avera.org
-
Ledende efterforsker:
- Ryan A. Vaca
-
Pierre, South Dakota, Forenede Stater, 57501
- Rekruttering
- Avera Cancer Institute at Pierre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-mail: OncRegulatory@avera.org
-
Ledende efterforsker:
- Ryan A. Vaca
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Rekruttering
- Avera Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-mail: OncRegulatory@avera.org
-
Ledende efterforsker:
- Ryan A. Vaca
-
Yankton, South Dakota, Forenede Stater, 57078
- Rekruttering
- Avera Cancer Institute at Yankton
-
Ledende efterforsker:
- Ryan A. Vaca
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-655-1800
- E-mail: OncRegulatory@avera.org
-
-
Texas
-
Baytown, Texas, Forenede Stater, 77521
- Rekruttering
- Houston Methodist San Jacinto Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Ledende efterforsker:
- Patrick E. Prath
-
Cypress, Texas, Forenede Stater, 77429
- Rekruttering
- Houston Methodist Cypress Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 346-356-1413
- E-mail: irb@houstonmethodist.org
-
Ledende efterforsker:
- Patrick E. Prath
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Ledende efterforsker:
- Suzanne M. Cole
-
Dallas, Texas, Forenede Stater, 75235
- Rekruttering
- Parkland Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-590-5582
- E-mail: canceranswerline@UTSouthwestern.edu
-
Ledende efterforsker:
- Suzanne M. Cole
-
Dallas, Texas, Forenede Stater, 75237
- Rekruttering
- UT Southwestern Simmons Cancer Center - RedBird
-
Ledende efterforsker:
- Suzanne M. Cole
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-mail: canceranswerline@utsouthwestern.edu
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Ledende efterforsker:
- Suzanne M. Cole
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Houston Methodist Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-790-2700
-
Ledende efterforsker:
- Patrick E. Prath
-
Houston, Texas, Forenede Stater, 77070
- Rekruttering
- Methodist Willowbrook Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Ledende efterforsker:
- Patrick E. Prath
-
Houston, Texas, Forenede Stater, 77094
- Rekruttering
- Houston Methodist West Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 832-522-2873
-
Ledende efterforsker:
- Patrick E. Prath
-
Nassau Bay, Texas, Forenede Stater, 77058
- Rekruttering
- Houston Methodist Saint John Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Ledende efterforsker:
- Patrick E. Prath
-
Richardson, Texas, Forenede Stater, 75080
- Rekruttering
- UT Southwestern Clinical Center at Richardson/Plano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-669-7044
- E-mail: Suzanne.cole@utsouthwestern.edu
-
Ledende efterforsker:
- Suzanne M. Cole
-
Sugar Land, Texas, Forenede Stater, 77479
- Rekruttering
- Houston Methodist Sugar Land Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 281-242-2873
-
Ledende efterforsker:
- Patrick E. Prath
-
The Woodlands, Texas, Forenede Stater, 77385
- Rekruttering
- Houston Methodist The Woodlands Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-790-2700
- E-mail: hmthewoodlands@houstonmethodist.org
-
Ledende efterforsker:
- Patrick E. Prath
-
-
Vermont
-
Berlin Corners, Vermont, Forenede Stater, 05602
- Rekruttering
- Central Vermont Medical Center/National Life Cancer Treatment
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-225-5400
-
Ledende efterforsker:
- Rahul Anil
-
Burlington, Vermont, Forenede Stater, 05401
- Rekruttering
- University of Vermont Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-4101
- E-mail: rpo@uvm.edu
-
Ledende efterforsker:
- Rahul Anil
-
Burlington, Vermont, Forenede Stater, 05405
- Rekruttering
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-mail: rpo@uvm.edu
-
Ledende efterforsker:
- Rahul Anil
-
Saint Johnsbury, Vermont, Forenede Stater, 05819
- Rekruttering
- Dartmouth Cancer Center - North
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-mail: cancer.research.nurse@hitchcock.org
-
Ledende efterforsker:
- Jacob B. Reibel
-
-
Virginia
-
Fredericksburg, Virginia, Forenede Stater, 22408
- Rekruttering
- Hematology Oncology Associates of Fredericksburg Inc
-
Kontakt:
- Site Public Contact
- Telefonnummer: 540-371-0079
- E-mail: cvaughn@hoafredericksburg.com
-
Ledende efterforsker:
- Asit K. Paul
-
Richmond, Virginia, Forenede Stater, 23229
- Rekruttering
- Virginia Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-287-3000
- E-mail: smoore@vacancer.com
-
Ledende efterforsker:
- Asit K. Paul
-
Richmond, Virginia, Forenede Stater, 23235
- Rekruttering
- VCU Massey Cancer Center at Stony Point
-
Kontakt:
- Site Public Contact
- E-mail: ctoclinops@vcu.edu
-
Ledende efterforsker:
- Asit K. Paul
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- VCU Massey Comprehensive Cancer Center
-
Ledende efterforsker:
- Asit K. Paul
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, Forenede Stater, 98004
- Rekruttering
- FHCC Overlake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 425-454-2148
-
Ledende efterforsker:
- Mikhail G. Perlov
-
Kirkland, Washington, Forenede Stater, 98034
- Rekruttering
- FHCC at EvergreenHealth
-
Ledende efterforsker:
- Prakash Varadarajan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 425-899-6000
-
Seattle, Washington, Forenede Stater, 98195
- Rekruttering
- University of Washington Medical Center - Montlake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Ledende efterforsker:
- Petros Grivas
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Ledende efterforsker:
- Petros Grivas
-
Seattle, Washington, Forenede Stater, 98133
- Rekruttering
- FHCC at Northwest Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-606-5800
-
Ledende efterforsker:
- Nellowe Candelario
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Rekruttering
- Vandalia Health/CAMC Institute for Academic Medicine
-
Ledende efterforsker:
- Kok Hoe Chan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-388-9944
- E-mail: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Forenede Stater, 54911
- Rekruttering
- ThedaCare Regional Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3604
- E-mail: ResearchDept@thedacare.org
-
Ledende efterforsker:
- Joyce Philip
-
Ashland, Wisconsin, Forenede Stater, 54806
- Rekruttering
- Duluth Clinic Ashland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Ledende efterforsker:
- Bret E. Friday
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Rekruttering
- Gundersen Lutheran Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 608-775-2385
- E-mail: cancerctr@gundersenhealth.org
-
Ledende efterforsker:
- Kurt Oettel
-
New Richmond, Wisconsin, Forenede Stater, 54017
- Rekruttering
- Cancer Center of Western Wisconsin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Ledende efterforsker:
- David M. King
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Patient must be ≥ 18 years of age
-
Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
-
Patient must have locally advanced (unresectable and/or not amenable to curative intent therapy) or metastatic urothelial cancer
-
Patient must have histologically (or based on urine cytology) proven conventional urothelial carcinoma (UC) of any urinary tract origin [any histologic subtype except neuroendocrine (small or large cell)] are permitted so long as tumors include ≥ 1% conventional urothelial histology). NOTE: Pure non-urothelial histology is excluded
-
Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Baseline imaging must be obtained ≤ 35 days prior to randomization
-
Patient must have the following prior treatment(s). Patient must have had progression on or after the immediate prior anti-cancer therapy
-
Patient must have had prior exposure to anti-PD(L)1 therapy [anti -PD(L)1 monotherapy or as a combination regimen in any disease/therapy setting for UC]. Patients must have received at least 1 dose of anti-PD(L)1 therapy
- NOTE: Anti-PD(L)1 therapy does not need to be the most recent therapy received prior to enrollment on this protocol
- NOTE: Patient must not have had progression within 12 weeks of starting their first anti-PD(L) 1 therapy, even if anti-PD-(L)1 treatment was given in more than one lines of therapy
-
Patient must have had ≥ 1 line of systemic therapy given in the advanced/metastatic disease setting, except for patients who had received anti-PD(L)1 + enfortumab vedotin in the localized disease setting (e.g., neoadjuvant and/or adjuvant) and had cancer progression within 12 months from the last systemic therapy dose
-
For tumors with known FGFR3+ susceptible alteration (for FGFR inhibitor), patients must have received a prior FGFR inhibitor unless contraindicated per physician discretion
-
Patient must have received prior enfortumab vedotin or any other Nectin-4 directed therapy or other MMAE-containing therapy in any disease/therapy setting unless contraindicated per physician
-
Patient must have had no prior exposure to Sacituzumab govitecan-hziy or other TROP-2 directed therapies or antibody-drug conjugate that contains topo-isomerase I inhibitor, e.g. trastuzumab deruxtecan
-
Patient must have Bellmunt score of 0-2. The Bellmunt score assesses a patient's risk and is calculated based on ECOG PS, hemoglobin level and presence of liver metastases
-
Patient must not have history of grade 3-4 immune-related adverse events on prior anti-PD1/L1, except for endocrinopathies on adequate hormone therapy repletion and/or clinically insignificant laboratory abnormalities
-
Patient must have recovered (i.e., ≤ grade 1) from clinically significant AEs due to previously administered systemic therapy agent, except for endocrinopathies on adequate hormone therapy repletion
-
NOTE: Patients with ≤ grade 2 neuropathy, any grade of alopecia, or any grade of non-clinically significant laboratory abnormality are exceptions to this criterion and are allowed in this trial.
-
Examples of non-clinically significant laboratory abnormalities include, but are not limited to:
- Lymphopenia or monopenia
- Lymphocytosis or monocytosis
- Increase in amylase or lipase with no clinical correlation
- Any other abnormal laboratory findings that have no clinical relevance per the treating investigator.
-
NOTE: If patient has undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to randomization
-
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Patient must not nurse infants while on protocol treatment and for 4 months after the last dose of protocol treatment
-
Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue contraceptive method(s) or abstain for 6 months after the last dose of protocol treatment. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of protocol treatment
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Absolute neutrophil count (ANC) ≥ 1,500/uL (obtained ≤ 14 days prior to randomization)
-
Platelets ≥ 100,000/uL (obtained ≤ 14 days prior to randomization)
-
Albumin ≥ 3 g/dL (obtained ≤ 14 days prior to randomization)
-
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to randomization)
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN or ≤ 5.0 x institutional ULN if known liver metastases (obtained ≤ 14 days prior to randomization)
-
Creatinine clearance (CrCl) ≥ 30 mL/min (obtained ≤ 14 days prior to randomization) NOTE: CrCl is estimated using the Cockcroft-Gault formula (or can be measured by 24-hour urine collection if needed)
-
Hemoglobin (Hb) ≥ 8.5 g/dl (obtained ≤ 14 days prior to randomization)
-
Patient must not have a known genetic UGT1A1 *28/*28 or *6/*6 homozygous variant genotype. Patients with homozygous variant types are considered poor metabolizers and are at higher risk for severe adverse events when compared to wild-type. Patients with heterozygous UGT1A1 variants (i.e. *1/*28 or *1/*6) are eligible and should be counseled accordingly and be very closely monitored if randomized to the sacituzumab govitecan arm
- NOTE: If a patient's UGT1A1 status is unknown, they are eligible to enroll (the study does not require this test as part of screening)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with history of hepatitis C virus (HCV) infection must have been treated and considered cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are not using steroids > 10 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to randomization
-
Patients with prior or concurrent malignancy that is not considered clinically significant and whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (at the discretion of the treating physician) are eligible
-
Patient must not be on systemic immunosuppressive medication, including steroids (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids, e.g. "burst", which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal, intra-articular and/or topical steroids are eligible
-
Patient must be English or Spanish speaking to be eligible for the HRQOL component of the study.
- NOTE: Sites cannot translate the associated HRQOL forms
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Arm I (TPC chemotherapy)
Patients receive TPC with carboplatin or cisplatin IV on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and CT or MRI throughout the study. |
Given IV
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Given IV
Andre navne:
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Given IV
Andre navne:
|
|
Eksperimentel: Arm II (pembrolizumab, sacituzumab govitecan-hziy)
Patients receive pembrolizumab IV over 30 minutes on day 1 and sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study. |
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Given IV
Andre navne:
Given IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS)
Tidsramme: From randomization to death due to any cause, assessed up to 5 years
|
OS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The hazard ratio (HR) will be estimated, and a 95% confidence interval (CI) will be reported. |
From randomization to death due to any cause, assessed up to 5 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS)
Tidsramme: From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
PFS will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PFS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
|
Overall response rate (ORR)
Tidsramme: Up to 5 years
|
ORR will be assessed among patients who received at least one dose of protocol therapy using RECIST v 1.1 criteria. ORR will be defined as the number of patients with complete response (CR) and partial response (PR) divided by the number of treated patients. ORR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Clinical benefit rate (CBR)
Tidsramme: Up to 5 years
|
CBR will be defined as CR, PR, or stable disease per RECIST v 1.1. CBR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Duration of response (DOR)
Tidsramme: From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
DOR will be assessed by RECIST v1.1. DOR will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
|
Incidence of adverse events (AEs)
Tidsramme: Up to 30 days after last dose of study drug
|
AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The percentage of patients with toxicities will be tabulated. The 90% CI for the true probability of observing toxicity of ≥ grade 4 on a given arm will be no wider than 12.3 %. The probability of observing ≥ 1 toxicity on a given arm with a true rate of 1% is 85.5%. |
Up to 30 days after last dose of study drug
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score
Tidsramme: At baseline and at 3, 6 and 12 months
|
Change in patient reported FBISI-18 score will be compared between arms using a two-sample t-test. Assessment time will be considered as a continuous variable if there is a linear trend in quality of life (QOL) assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. A t-test will be performed to explore change of FBISI-18 summary score. |
At baseline and at 3, 6 and 12 months
|
|
Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) summary score
Tidsramme: At baseline and at 3, 6 and 12 months
|
Change in patient reported FACIT-F score will be compared between arms using a two-sample t-test. Mixed effect models will be constructed to estimate the time profile of FACIT-F in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in QOL assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. |
At baseline and at 3, 6 and 12 months
|
|
Change in quality-adjusted survival (assessed by the European Quality of Life Five Dimension Five Level scale [EQ-5D-5L]).
Tidsramme: At baseline and at 3, 6 and 12 months
|
Change in patient reported EQ-5D-5L will be compared between the arms using a two-sample t-test. Quality-adjusted survival (assessed by the EQ-5D-5L), will be analyzed with quality-adjusted time without symptoms or toxicity. |
At baseline and at 3, 6 and 12 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Monika Joshi, ECOG-ACRIN Cancer Research Group
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Karcinom
- Carcinom, overgangscelle
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kulbrinter
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Uorganiske kemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinationskomplekser
- Taxoider
- Cyclodecanes
- Diterpenes
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Elementer
- Metaller
- Sundhedsøkonomi og organisationer
- Kemiteknikker, analytisk
- Spektrumanalyse
- Metaller, tung
- Platinforbindelser
- Overgangselementer
- Økonomi
- Docetaxel
- Gemcitabin
- Carboplatin
- Paclitaxel
- Cisplatin
- 1,2-diaminocyclohexanplatin II-citrat
- Håndtering af eksemplar
- pembrolizumab
- Magnetisk resonansspektroskopi
- Platinum
- Sacituzumab Govitecan
- Skatter
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NCI-2024-06208
- U10CA180820 (U.S. NIH-bevilling/kontrakt)
- NCI-2024-06208 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- EA8231 (Anden identifikator: CTEP)
- EA8231 (Anden identifikator: ECOG-ACRIN Cancer Research Group)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .